You are here

Shionogi

In-house FDA review flags a suspicious imbalance in deaths as Shionogi hunts an OK for antibiotic

In-house FDA review flags a suspicious imbalance in deaths as Shionogi hunts an OK for antibiotic

Endpoints

advisory panels

Flag link:

Shionogi celebrates antibiotic win in pneumonia just ahead of its date with FDA regulators

Shionogi celebrates antibiotic win in pneumonia just ahead of its date with FDA regulators

Endpoints

nosocomial pneumonia

Flag link:

Two years following US approval, Japan's Shionogi wins EU green light for opioid constipation drug

Two years following US approval, Japan's Shionogi wins EU green light for opioid constipation drug

Endpoints

opioid-induced constipation

Flag link:

FDA Approves First New Flu Drug in Nearly 20 Years

FDA Approves First New Flu Drug in Nearly 20 Years

CP Wire

Flag link:

FDA Approves First New Flu Drug in Nearly 20 Years

Flag link:

Fast-acting flu drug shows strong potential, but clinical trial results also raise concerns

Fast-acting flu drug shows strong potential, but clinical trial results also raise concerns

Stat

clinical trials

baloxavir marboxil

Flag link:

Shire, Shionogi File NDA for Intuniv for Adults in Japan

Shire, Shionogi File NDA for Intuniv for Adults in Japan

Yahoo/Zacks.com

Flag link:

FDA hustles through a quick OK for Shionogi’s new thrombocytopenia drug

FDA hustles through a quick OK for Shionogi’s new thrombocytopenia drug

Endpoints

thrombocytopenia

Flag link:

Roche’s antiviral hits flu targets in PhIII trial

Roche’s antiviral hits flu targets in PhIII trial

Pharma Times

baloxavir marboxil

Flag link:

The first single-dose flu drug nod could be FDA’s Christmas present for Roche

The first single-dose flu drug nod could be FDA’s Christmas present for Roche

Fierce Pharma

Flag link:

ViiV Healthcare reports positive results for late-stage HIV trials

ViiV Healthcare reports positive results for late-stage HIV trials

Marketwatch

ViiV Healthcare

clinical trials

Flag link:

On a roll, Sage grabs a $575M deal on limited Asian rights to SAGE-217 — a potential gamechanger in depression

On a roll, Sage grabs a $575M deal on limited Asian rights to SAGE-217 — a potential gamechanger in depression

Endpoints

SAGE Therapeutics

Flag link:

Shionogi’s flu drug wins green light in Japan, but U.S. approval not likely until 2019

Shionogi’s flu drug wins green light in Japan, but U.S. approval not likely until 2019

Fierce Pharma

Flag link:

Shionogi, Roche get their first approval for the next big thing in fighting the flu

Shionogi, Roche get their first approval for the next big thing in fighting the flu

Endpoints

Flag link:

Japan-based Shionogi develops powerful drug to treat influenza

Japan-based Shionogi develops powerful drug to treat influenza

GoinPharma

Flag link:

Crestor Developer Sees Sales Doubling On Lower-Priced Drugs

Crestor Developer Sees Sales Doubling On Lower-Priced Drugs

Bloomberg

Flag link:

The FDA issues warning letter to Shionogi over co-pay voucher

The FDA issues warning letter to Shionogi over co-pay voucher

Medical Marketing and Media

co-pay vouchers

Flag link:

Why ViiV Healthcare leads the pharma industry in corporate reputation

Why ViiV Healthcare leads the pharma industry in corporate reputation

BioPharma Dive

ViiV Healthcare

Flag link:

Roche looks beyond Tamiflu, striking deal for Shionogi's flu fighter

Roche looks beyond Tamiflu, striking deal for Shionogi's flu fighter

Fierce Pharma

Flag link:

Glaxo’s Best ‘Headache’ Remedy May Be Buying Stakes in Ventures

Glaxo’s Best ‘Headache’ Remedy May Be Buying Stakes in Ventures

Bloomberg

Flag link:

Pages